Please login to the form below
Alexion
This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.
2023 PM Society Awards – winners announced
Dermavant and GE Healthcare won two Golds each. Other Gold winners on the client side were Alexion, Campaign Against Living Miserably (CALM), CSF Vifor, Ethypharm, Mind, and Sanofi.
Latest news
-
AstraZeneca announces major expansion of Canadian research footprint
AstraZeneca (AZ) has announced a major expansion of its research footprint in Canada with the creation of 500 highly-skilled jobs and a new Alexion rare disease research hub. ... Alexion was acquired by AZ in July 2021, marking the Anglo-Swedish
-
AstraZeneca progresses application for $360m Ireland manufacturing site
Originally announced by the company in September 2021, the facility will be built at the Alexion Campus in College Park in Dublin and produce APIs – the substances in drugs that are ... Alexion was acquired by AZ in July 2021, marking the Anglo-Swedish
-
Roche reports positive results for crovalimab as rare blood disease treatment
C5 inhibitors can be effective in treating the condition. This includes AstraZeneca/Alexion's Soliris (eculizumab), which was approved by the US Food and Drug Administration in 2007 and has subsequently
-
Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022
The agreement, first reported by The Wall Street Journal, marks the largest transaction of its kind since Alexion’s buyout by AstraZeneca for $39bn in 2021.
-
Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial
Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an
More from news
Approximately 50 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Changing an organisation’s microfoundations – why capabilities count
Imagine, for example, Alexion’s rare disease business model trying to compete with, say, Viatris in generic small molecules, or vice versa.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
European biotech: a new generation of leaders emerges
Previously chief exec of Boston-based biotech Syntimmune, (acquired by Alexion in November last year) Kress will be in post to oversee the filing of MOR208 later this year, and its
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster
-
Drug launches to watch in 2019
Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
AZ appoints Alexion’s Aradhana Sarin as chief financial officer
Sarin will become AZ's new chief financial officer upon closing of the company’s acquisition of Alexion Pharmaceuticals. ... Prior to joining Alexion, she served as managing director, healthcare corporate &investment banking at Citi Global Banking.
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
Prior to CRISPR, he worked as head of translational medicine at Alexion Pharmaceuticals, and also served as chief medical officer of Taligen Therapeutics.
-
Abeona Therapeutics names CEO
Carsten Thiel joins the biopharma from Alexion. Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and
-
Amryt Pharma appoints Jordi Casals as head of Europe
Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.
-
Alexion Pharmaceuticals adds to its board
Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of
More from appointments
Approximately 4 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
Sanofi’s Isatuximab, and a potentially first-in-class fibril-reactive mAb from AstraZeneca’s Alexion division.
-
Evoke Mind+Matter
They include: Aerogen, Akcea, Allakos, Alexion, Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer, Biocryst, Biogen, Biomarin, Bio-Oil, Boehringer Ingelheim, Cryoport, Colgate Palmolive, CSL Behring, Eiger BioPharmaceuticals, EIT Health,
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
- Why everyone in pharma is bending over backwards to be agile
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
